Key result
COVID-19 mRNA vaccines linked to myocarditis and pericarditis after the second dose, comprising ~86% males.
Why the study?
Myocarditis can develop following exposure to SARS-CoV-2 and COVID-19 vaccines, prompting a review of diagnostic methods and clinical overview.
This review highlights the clinical presentation, diagnostic imaging criteria (such as the Lake Louise Criteria for CMR), and generally favorable prognosis of COVID-19 mRNA vaccine-induced myocarditis.
Answers are grounded in this paper and cite their sources.
Clinicians should maintain vigilance for myocarditis after SARS-CoV-2 exposure or vaccination; extends known etiologies and supports ongoing surveillance research.
Myocarditis is an inflammatory condition of the myocardium that develops secondary to various etiological factors; it is a disease with complications and mortality. Although the causes are infectious, immune-mediated, and drug-toxin exposure, it can also develop after exposed to the coronavirus 2 and coronavirus disease 2019 (COVID-19) vaccines, which recently affected the world and caused severe acute respiratory syndrome. In addition to clinical and laboratory findings, imaging methods, such as echocardiography, computed tomography angiography, and cardiac magnetic resonance imaging, play a significant role in diagnosis. In this article, myocarditis overview, diagnostic methods, post-COVID, and post-vaccine myocarditis were reviewed.
No takes yet. Share an insight, caveat, or question.
Sasani et al. (2022) conducted a review in COVID-19 mRNA vaccine-induced myocarditis. COVID-19 mRNA vaccines was evaluated. COVID-19 mRNA vaccines can induce myocarditis and pericarditis, predominantly in males, with symptoms typically appearing within a few days after the second dose and most patients recovering fully.
Synapse has enriched 10 related papers. Consider them for comparative context: